Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disea...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 139; no. 4; pp. 492 - 501
Main Authors San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, Bahlis, Nizar J.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 27.01.2022
American Society of Hematology
Subjects
Aged
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Clinical Trials and Observations
Female
Humans
Male
Middle Aged
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Neoplasm, Residual - diagnosis
Neoplasm, Residual - drug therapy
Progression-Free Survival
Treatment Outcome
Online AccessGet full text

Cover

Abstract In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10−5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE). •In patients with transplant-ineligible NDMM, durable MRD negativity is associated with improved PFS.•Daratumumab-based therapies are associated with higher rates and durability of MRD negativity. [Display omitted]
AbstractList In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10-5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10−5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE). •In patients with transplant-ineligible NDMM, durable MRD negativity is associated with improved PFS.•Daratumumab-based therapies are associated with higher rates and durability of MRD negativity. [Display omitted]
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10-5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10-5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10−5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
San Miguel et al evaluated the impact of dynamic, rather than single-point, assessment of measurable/minimal residual disease (MRD) by next-generation sequencing at a sensitivity of 10 −5 during remission on outcome in over 1400 patients in 2 randomized trials of first-line myeloma therapy. MRD negativity sustained over 12 months is associated with superior progression-free survival over either MRD positivity or nonsustained MRD negativity, regardless of frontline treatment regimen. In patients with transplant-ineligible NDMM, durable MRD negativity is associated with improved PFS. Daratumumab-based therapies are associated with higher rates and durability of MRD negativity. In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10 −5 ) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥ 6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
Author San-Miguel, Jesus
Pei, Huiling
Cavo, Michele
Qi, Ming
Wang, Jianping
Krevvata, Maria
Dimopoulos, Meletios A.
Van Rampelbergh, Rian
Paiva, Bruno
Avet-Loiseau, Hervé
Jakubowiak, Andrzej
Mateos, María-Victoria
Heuck, Christoph
Kobos, Rachel
Ramaswami, Priya
Ukropec, Jon
DeAngelis, Nikki
Usmani, Saad Z.
Touzeau, Cyrille
Kudva, Anupa
Sun, Steven
Facon, Thierry
Qi, Mia
Kumar, Shaji
Quach, Hang
Cook, Gordon
Bahlis, Nizar J.
AuthorAffiliation 13 Janssen Global Medical Affairs, Horsham, PA
18 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
5 University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
6 University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
15 Janssen Research & Development, LLC, Raritan, NJ
1 Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
7 Hematology, University Hospital Hôtel-Dieu, Nantes, France
4 National and Kapodistrian University of Athens, Athens, Greece
3 Department of Hematology, Mayo Clinic, Rochester, MN
10 Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom
14 Janssen Research & Development, LLC, Titusville, NJ
12 University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC
9 Levine Cancer Institute/Atrium Health, Charlo
AuthorAffiliation_xml – name: 14 Janssen Research & Development, LLC, Titusville, NJ
– name: 17 Janssen Research & Development, Beerse, Belgium; and
– name: 6 University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
– name: 12 University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC
– name: 4 National and Kapodistrian University of Athens, Athens, Greece
– name: 9 Levine Cancer Institute/Atrium Health, Charlotte, NC
– name: 8 University of Chicago Medical Center, Chicago, IL
– name: 10 Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom
– name: 13 Janssen Global Medical Affairs, Horsham, PA
– name: 2 Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
– name: 16 Janssen Research & Development, LLC, Spring House, PA
– name: 11 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Università di Bologna, Bologna, Italy
– name: 7 Hematology, University Hospital Hôtel-Dieu, Nantes, France
– name: 15 Janssen Research & Development, LLC, Raritan, NJ
– name: 1 Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
– name: 5 University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
– name: 3 Department of Hematology, Mayo Clinic, Rochester, MN
– name: 18 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
Author_xml – sequence: 1
  givenname: Jesus
  orcidid: 0000-0002-9183-4857
  surname: San-Miguel
  fullname: San-Miguel, Jesus
  email: sanmiguel@unav.es
  organization: Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
– sequence: 2
  givenname: Hervé
  surname: Avet-Loiseau
  fullname: Avet-Loiseau, Hervé
  organization: Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
– sequence: 3
  givenname: Bruno
  orcidid: 0000-0003-1977-3815
  surname: Paiva
  fullname: Paiva, Bruno
  organization: Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
– sequence: 4
  givenname: Shaji
  orcidid: 0000-0001-5392-9284
  surname: Kumar
  fullname: Kumar, Shaji
  organization: Department of Hematology, Mayo Clinic, Rochester, MN
– sequence: 5
  givenname: Meletios A.
  surname: Dimopoulos
  fullname: Dimopoulos, Meletios A.
  organization: National and Kapodistrian University of Athens, Athens, Greece
– sequence: 6
  givenname: Thierry
  surname: Facon
  fullname: Facon, Thierry
  organization: University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
– sequence: 7
  givenname: María-Victoria
  orcidid: 0000-0003-2390-1218
  surname: Mateos
  fullname: Mateos, María-Victoria
  organization: University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
– sequence: 8
  givenname: Cyrille
  surname: Touzeau
  fullname: Touzeau, Cyrille
  organization: Hematology, University Hospital Hôtel-Dieu, Nantes, France
– sequence: 9
  givenname: Andrzej
  surname: Jakubowiak
  fullname: Jakubowiak, Andrzej
  organization: University of Chicago Medical Center, Chicago, IL
– sequence: 10
  givenname: Saad Z.
  surname: Usmani
  fullname: Usmani, Saad Z.
  organization: Levine Cancer Institute/Atrium Health, Charlotte, NC
– sequence: 11
  givenname: Gordon
  surname: Cook
  fullname: Cook, Gordon
  organization: Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom
– sequence: 12
  givenname: Michele
  surname: Cavo
  fullname: Cavo, Michele
  organization: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Università di Bologna, Bologna, Italy
– sequence: 13
  givenname: Hang
  orcidid: 0000-0002-4796-3352
  surname: Quach
  fullname: Quach, Hang
  organization: University of Melbourne, St. Vincent's Hospital, Melbourne, VIC
– sequence: 14
  givenname: Jon
  surname: Ukropec
  fullname: Ukropec, Jon
  organization: Janssen Global Medical Affairs, Horsham, PA
– sequence: 15
  givenname: Priya
  surname: Ramaswami
  fullname: Ramaswami, Priya
  organization: Janssen Research & Development, LLC, Titusville, NJ
– sequence: 16
  givenname: Huiling
  surname: Pei
  fullname: Pei, Huiling
  organization: Janssen Research & Development, LLC, Titusville, NJ
– sequence: 17
  givenname: Mia
  surname: Qi
  fullname: Qi, Mia
  organization: Janssen Research & Development, LLC, Raritan, NJ
– sequence: 18
  givenname: Steven
  surname: Sun
  fullname: Sun, Steven
  organization: Janssen Research & Development, LLC, Raritan, NJ
– sequence: 19
  givenname: Jianping
  surname: Wang
  fullname: Wang, Jianping
  organization: Janssen Research & Development, LLC, Raritan, NJ
– sequence: 20
  givenname: Maria
  surname: Krevvata
  fullname: Krevvata, Maria
  organization: Janssen Research & Development, LLC, Spring House, PA
– sequence: 21
  givenname: Nikki
  surname: DeAngelis
  fullname: DeAngelis, Nikki
  organization: Janssen Research & Development, LLC, Spring House, PA
– sequence: 22
  givenname: Christoph
  surname: Heuck
  fullname: Heuck, Christoph
  organization: Janssen Research & Development, LLC, Spring House, PA
– sequence: 23
  givenname: Rian
  surname: Van Rampelbergh
  fullname: Van Rampelbergh, Rian
  organization: Janssen Research & Development, Beerse, Belgium
– sequence: 24
  givenname: Anupa
  surname: Kudva
  fullname: Kudva, Anupa
  organization: Janssen Research & Development, LLC, Raritan, NJ
– sequence: 25
  givenname: Rachel
  surname: Kobos
  fullname: Kobos, Rachel
  organization: Janssen Research & Development, LLC, Raritan, NJ
– sequence: 26
  givenname: Ming
  surname: Qi
  fullname: Qi, Ming
  organization: Janssen Research & Development, LLC, Spring House, PA
– sequence: 27
  givenname: Nizar J.
  surname: Bahlis
  fullname: Bahlis, Nizar J.
  organization: Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34269818$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1vFCEYJqbGbqt3T2aOXqYCM8wMHkw2m6pNVntQD54IAy9bDAMrMGv27B-X7bZ-JXrihff5CM9zhk588IDQU4IvCBnoi9GFoC8ophgT3Db8AVoQRocal5cTtMAYd3XLe3KKzlL6UkBtQ9kjdNq0tOMDGRbo-4c5ZWk96Gqy3k7SVRGS1XMZtE0gE1QeNjLbnc37yvpy--b2ZSc3PqQDbXbZbh1U0x5cmGQlva7yDVR22kqVq2AqLaPM8zRPcjwovFteLW9Ry_Xq8_X7y8fooZEuwZO78xx9en35cfW2Xl-_uVot17VipMl1M0pmeGu07AnttW41G3stDeZsGBso0yhNBwRI22PCVcOMIQR4rxpDFR-ac_TqqLudxwm0Ap-jdGIby7fjXgRpxZ8bb2_EJuzE0POuY10ReH4nEMPXGVIWk00KnJMewpwEZYxyzhjmBfrsd6-fJvfJF0B3BKgYUopghLK5xBwO1tYJgsWhYnFbsfhVcSHiv4j32v-hvDxSoKS7sxBFUha8Am0jqCx0sP8m_wC4EcDZ
CitedBy_id crossref_primary_10_3390_cancers15072060
crossref_primary_10_1177_15330338241252605
crossref_primary_10_1038_s41375_023_01936_7
crossref_primary_10_1182_hematology_2022000347
crossref_primary_10_1182_hem_V22_1_202511
crossref_primary_10_1182_hematology_2022000348
crossref_primary_10_1177_10781552231176499
crossref_primary_10_1111_ejh_14316
crossref_primary_10_1111_bjh_18211
crossref_primary_10_26442_18151434_2024_4_203086
crossref_primary_10_1080_10428194_2025_2455485
crossref_primary_10_1182_blood_2024024995
crossref_primary_10_1038_s41375_024_02505_2
crossref_primary_10_1038_s41591_024_03050_2
crossref_primary_10_1007_s11912_024_01545_2
crossref_primary_10_3390_hemato3030027
crossref_primary_10_3390_cancers17060944
crossref_primary_10_1080_17474086_2021_1983426
crossref_primary_10_1182_blood_2023022080
crossref_primary_10_3390_ph18020159
crossref_primary_10_1016_j_cca_2023_117623
crossref_primary_10_1002_hon_3041
crossref_primary_10_1182_blood_2023022083
crossref_primary_10_1007_s12672_024_00891_8
crossref_primary_10_3390_cancers16051024
crossref_primary_10_1016_j_clml_2025_01_014
crossref_primary_10_17925_OHR_2022_18_2_96
crossref_primary_10_1200_JCO_25_00048
crossref_primary_10_3389_fonc_2024_1286029
crossref_primary_10_1158_1078_0432_CCR_23_2767
crossref_primary_10_1016_j_clml_2025_01_010
crossref_primary_10_1177_17588359231221340
crossref_primary_10_1016_j_clinme_2024_100252
crossref_primary_10_1182_blood_2022016782
crossref_primary_10_58931_cht_2023_2121
crossref_primary_10_1016_S2352_3026_23_00236_3
crossref_primary_10_1007_s44228_023_00036_8
crossref_primary_10_1182_blood_2022017635
crossref_primary_10_3390_cancers16193288
crossref_primary_10_1182_bloodadvances_2024014097
crossref_primary_10_1038_s43018_023_00657_1
crossref_primary_10_3390_hemato5020010
crossref_primary_10_1080_10428194_2024_2322030
crossref_primary_10_1016_j_clml_2023_02_005
crossref_primary_10_1080_14740338_2023_2296966
crossref_primary_10_1007_s11912_024_01537_2
crossref_primary_10_3390_cancers16122263
crossref_primary_10_1182_blood_2023020284
crossref_primary_10_3390_ijms232415879
crossref_primary_10_1016_j_yao_2022_02_012
crossref_primary_10_1182_blood_2024025746
crossref_primary_10_3390_cancers15082203
crossref_primary_10_3389_fonc_2022_830922
crossref_primary_10_1182_blood_2022016170
crossref_primary_10_1371_journal_pone_0285696
crossref_primary_10_1182_blood_2022018394
crossref_primary_10_1055_s_0043_1768176
crossref_primary_10_1038_s41408_022_00750_1
crossref_primary_10_1002_cam4_6640
crossref_primary_10_1182_blood_2024024371
crossref_primary_10_3390_cancers15102693
crossref_primary_10_1016_S2352_3026_23_00240_5
crossref_primary_10_1097_HS9_0000000000000942
crossref_primary_10_1182_blood_2021013363
crossref_primary_10_36290_xon_2022_057
crossref_primary_10_3390_cells13100853
crossref_primary_10_1038_s41420_024_01818_6
crossref_primary_10_1158_2767_9764_CRC_23_0185
crossref_primary_10_3390_cancers15143687
crossref_primary_10_1038_s41408_024_01156_x
crossref_primary_10_1080_10428194_2023_2255325
crossref_primary_10_1007_s00277_024_06143_7
crossref_primary_10_1200_JCO_23_01696
crossref_primary_10_1111_bjh_18226
crossref_primary_10_1177_20406207251314289
crossref_primary_10_1056_NEJMoa2203478
crossref_primary_10_1016_j_eclinm_2023_102016
crossref_primary_10_1182_blood_2020008733
crossref_primary_10_3390_biomedicines11072087
crossref_primary_10_1016_j_lpm_2024_104261
crossref_primary_10_1200_JCO_24_00635
crossref_primary_10_2169_naika_112_1216
crossref_primary_10_3389_fonc_2021_800309
crossref_primary_10_1016_j_lpm_2024_104266
crossref_primary_10_1182_hematology_2023000444
crossref_primary_10_3389_fphar_2024_1398879
crossref_primary_10_1016_j_cll_2023_05_003
crossref_primary_10_1158_1078_0432_CCR_22_1681
crossref_primary_10_1038_s43018_024_00821_1
crossref_primary_10_1038_s41408_023_00939_y
crossref_primary_10_1182_blood_2021013199
crossref_primary_10_3892_ol_2024_14681
crossref_primary_10_1007_s12185_022_03353_5
crossref_primary_10_1016_j_hoc_2023_12_009
crossref_primary_10_1097_CCO_0000000000001091
Cites_doi 10.1038/s41375-020-0855-4
10.1182/blood-2018-06-858613
10.1182/blood-2015-12-687749
10.1080/19420862.2015.1007813
10.1016/S0140-6736(19)32956-3
10.1182/blood-2014-01-550020
10.1200/JCO.2016.69.2517
10.1200/JCO.2012.46.2119
10.1056/NEJMoa1714678
10.1016/j.clml.2019.09.622
10.1182/blood-2008-05-159624
10.1016/S1470-2045(14)70442-5
10.1056/NEJMoa1611750
10.1002/cyto.a.23693
10.4049/jimmunol.1003032
10.1056/NEJMoa1817249
10.1182/blood.V124.21.3474.3474
10.4049/jimmunol.1501351
10.1038/sj.leu.2404284
10.1016/S1470-2045(16)30206-6
10.3389/fonc.2020.00860
10.1001/jamaoncol.2016.3160
10.1038/bmt.2016.222
10.1182/blood-2010-10-299487
ContentType Journal Article
Copyright 2022 American Society of Hematology
2022 by The American Society of Hematology.
2022 by The American Society of Hematology 2022
Copyright_xml – notice: 2022 American Society of Hematology
– notice: 2022 by The American Society of Hematology.
– notice: 2022 by The American Society of Hematology 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1182/blood.2020010439
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 501
ExternalDocumentID PMC8796656
34269818
10_1182_blood_2020010439
S0006497121013689
Genre Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P01 CA155258
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6J9
AAEDW
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFOSN
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
AALRI
AAYXX
ACVFH
ADCNI
ADVLN
AEUPX
AFETI
AFPUW
AGCQF
AIGII
AITUG
AKBMS
AKRWK
AKYEP
CITATION
H13
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c513t-3ba5f94fda7127dd4d5b7daf0958b3edafbaf6e1e147019c35ff11e97c3f2c983
ISSN 0006-4971
1528-0020
IngestDate Thu Aug 21 17:25:23 EDT 2025
Thu Jul 10 23:40:20 EDT 2025
Mon Jul 21 05:45:29 EDT 2025
Thu Apr 24 23:04:29 EDT 2025
Tue Jul 01 00:19:42 EDT 2025
Fri Feb 23 02:39:49 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License 2022 by The American Society of Hematology.
This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c513t-3ba5f94fda7127dd4d5b7daf0958b3edafbaf6e1e147019c35ff11e97c3f2c983
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-4796-3352
0000-0003-1977-3815
0000-0001-5392-9284
0000-0002-9183-4857
0000-0003-2390-1218
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8796656
PMID 34269818
PQID 2552995509
PQPubID 23479
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8796656
proquest_miscellaneous_2552995509
pubmed_primary_34269818
crossref_citationtrail_10_1182_blood_2020010439
crossref_primary_10_1182_blood_2020010439
elsevier_sciencedirect_doi_10_1182_blood_2020010439
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-01-27
20220127
PublicationDateYYYYMMDD 2022-01-27
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-27
  day: 27
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington, DC
PublicationTitle Blood
PublicationTitleAlternate Blood
PublicationYear 2022
Publisher Elsevier Inc
American Society of Hematology
Publisher_xml – name: Elsevier Inc
– name: American Society of Hematology
References Gay F, Musto P, Rota Scalabrini D, et al. Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized FORTE trial [abstract]. Blood. 2020;136(suppl 1):35-37.
Avet-Loiseau, Ludwig, Landgren (bib9) 2020; 20
Rawstron, Child, de Tute (bib3) 2013; 31
Munshi, Avet-Loiseau, Rawstron (bib6) 2017; 3
de Weers, Tai, van der Veer (bib14) 2011; 186
Attal, Lauwers-Cances, Hulin, IFM 2009 Study (bib1) 2017; 376
Krejcik, Casneuf, Nijhof (bib18) 2016; 128
Adams, Stevenaert, Krejcik (bib19) 2019; 95
Kostopoulos, Ntanasis-Stathopoulos, Gavriatopoulou, Tsitsilonis, Terpos (bib12) 2020; 10
Lammerts van Bueren, Jakobs, Kaldenhoven (bib15) 2014; 124
Paiva, Vidriales, Cerveró, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups (bib2) 2008; 112
Perrot, Lauwers-Cances, Corre (bib8) 2018; 132
Mateos, Dimopoulos, Cavo, ALCYONE Trial Investigators (bib23) 2018; 378
Mateos, Cavo, Blade (bib11) 2020; 395
Bahlis N, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant: updated analysis of MAIA. In: Proceedings from the 61st American Society of Hematology Annual Meeting & Exposition; 7-10 December 2019; Orlando, FL.
Martinez-Lopez, Lahuerta, Pepin (bib4) 2014; 123
Rajkumar, Harousseau, Durie, International Myeloma Workshop Consensus Panel 1 (bib26) 2011; 117
Adaptive Biotechnologies Corporation,. clonoSEQ® Assay Technical Information., New York, NY: Adaptive Biotechnologies Corporation; 2018.
Darzalex (daratumumab) (bib21) 2020
Landgren, Devlin, Boulad, Mailankody (bib7) 2016; 51
Kumar, Paiva, Anderson (bib13) 2016; 17
Overdijk, Verploegen, Bögels (bib16) 2015; 7
Rajkumar, Dimopoulos, Palumbo (bib24) 2014; 15
Durie, Harousseau, Miguel, International Myeloma Working Group (bib25) 2006; 20
Facon, Kumar, Plesner, MAIA Trial Investigators (bib10) 2019; 380
Casneuf, Adams, van de Donk (bib20) 2020; 35
Overdijk, Jansen, Nederend (bib17) 2016; 197
Lahuerta, Paiva, Vidriales, GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group (bib5) 2017; 35
Paiva (2022012716231840800_B2) 2008; 112
Darzalex (daratumumab) (2022012716231840800_B21) 2020
Munshi (2022012716231840800_B6) 2017; 3
Facon (2022012716231840800_B10) 2019; 380
Lahuerta (2022012716231840800_B5) 2017; 35
Attal (2022012716231840800_B1) 2017; 376
Avet-Loiseau (2022012716231840800_B9) 2020; 20
Overdijk (2022012716231840800_B16) 2015; 7
Rajkumar (2022012716231840800_B26) 2011; 117
Adaptive Biotechnologies Corporation (2022012716231840800_B27) 2018
Lammerts van Bueren (2022012716231840800_B15) 2014; 124
Gay (2022012716231840800_B28) 2020; 136
Rajkumar (2022012716231840800_B24) 2014; 15
Kostopoulos (2022012716231840800_B12) 2020; 10
Mateos (2022012716231840800_B11) 2020; 395
Durie (2022012716231840800_B25) 2006; 20
Perrot (2022012716231840800_B8) 2018; 132
Kumar (2022012716231840800_B13) 2016; 17
Martinez-Lopez (2022012716231840800_B4) 2014; 123
Adams (2022012716231840800_B19) 2019; 95
Rawstron (2022012716231840800_B3) 2013; 31
de Weers (2022012716231840800_B14) 2011; 186
Mateos (2022012716231840800_B23) 2018; 378
Landgren (2022012716231840800_B7) 2016; 51
Casneuf (2022012716231840800_B20) 2020; 35
Krejcik (2022012716231840800_B18) 2016; 128
Overdijk (2022012716231840800_B17) 2016; 197
2022012716231840800_B22
35084473 - Blood. 2022 Jan 27;139(4):469-471. doi: 10.1182/blood.2021013199
References_xml – volume: 35
  start-page: 2900
  year: 2017
  end-page: 2910
  ident: bib5
  article-title: Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials
  publication-title: J Clin Oncol.
– volume: 117
  start-page: 4691
  year: 2011
  end-page: 4695
  ident: bib26
  article-title: Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
  publication-title: Blood.
– volume: 20
  start-page: e30
  year: 2020
  end-page: e37
  ident: bib9
  article-title: Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis
  publication-title: Clin Lymphoma Myeloma Leuk.
– volume: 31
  start-page: 2540
  year: 2013
  end-page: 2547
  ident: bib3
  article-title: Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
  publication-title: J Clin Oncol.
– volume: 132
  start-page: 2456
  year: 2018
  end-page: 2464
  ident: bib8
  article-title: Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
  publication-title: Blood.
– volume: 35
  start-page: 573
  year: 2020
  end-page: 584
  ident: bib20
  article-title: Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
  publication-title: Leukemia.
– volume: 17
  start-page: e328
  year: 2016
  end-page: e346
  ident: bib13
  article-title: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
  publication-title: Lancet Oncol.
– volume: 128
  start-page: 384
  year: 2016
  end-page: 394
  ident: bib18
  article-title: Daratumumab depletes CD38
  publication-title: Blood.
– volume: 20
  start-page: 1467
  year: 2006
  end-page: 1473
  ident: bib25
  article-title: International uniform response criteria for multiple myeloma [corrections published in
  publication-title: Leukemia.
– volume: 15
  start-page: e538
  year: 2014
  end-page: e548
  ident: bib24
  article-title: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
  publication-title: Lancet Oncol.
– volume: 123
  start-page: 3073
  year: 2014
  end-page: 3079
  ident: bib4
  article-title: Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
  publication-title: Blood.
– volume: 197
  start-page: 807
  year: 2016
  end-page: 813
  ident: bib17
  article-title: The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking
  publication-title: J Immunol.
– volume: 378
  start-page: 518
  year: 2018
  end-page: 528
  ident: bib23
  article-title: Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
  publication-title: N Engl J Med.
– reference: Gay F, Musto P, Rota Scalabrini D, et al. Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized FORTE trial [abstract]. Blood. 2020;136(suppl 1):35-37.
– volume: 124
  start-page: 3474
  year: 2014
  ident: bib15
  article-title: Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
  publication-title: Blood.
– volume: 51
  start-page: 1565
  year: 2016
  end-page: 1568
  ident: bib7
  article-title: Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
  publication-title: Bone Marrow Transplant.
– volume: 7
  start-page: 311
  year: 2015
  end-page: 321
  ident: bib16
  article-title: Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
  publication-title: MAbs.
– volume: 95
  start-page: 279
  year: 2019
  end-page: 289
  ident: bib19
  article-title: High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action
  publication-title: Cytometry A.
– volume: 3
  start-page: 28
  year: 2017
  end-page: 35
  ident: bib6
  article-title: Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis
  publication-title: JAMA Oncol.
– volume: 376
  start-page: 1311
  year: 2017
  end-page: 1320
  ident: bib1
  article-title: Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma
  publication-title: N Engl J Med.
– volume: 380
  start-page: 2104
  year: 2019
  end-page: 2115
  ident: bib10
  article-title: Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
  publication-title: N Engl J Med.
– volume: 10
  start-page: 860
  year: 2020
  ident: bib12
  article-title: Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches
  publication-title: Front Oncol.
– volume: 186
  start-page: 1840
  year: 2011
  end-page: 1848
  ident: bib14
  article-title: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
  publication-title: J Immunol.
– volume: 395
  start-page: 132
  year: 2020
  end-page: 141
  ident: bib11
  article-title: Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
  publication-title: Lancet.
– reference: Adaptive Biotechnologies Corporation,. clonoSEQ® Assay Technical Information., New York, NY: Adaptive Biotechnologies Corporation; 2018.
– volume: 112
  start-page: 4017
  year: 2008
  end-page: 4023
  ident: bib2
  article-title: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
  publication-title: Blood.
– reference: Bahlis N, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant: updated analysis of MAIA. In: Proceedings from the 61st American Society of Hematology Annual Meeting & Exposition; 7-10 December 2019; Orlando, FL.
– year: 2020
  ident: bib21
  publication-title: Package insert.
– volume: 35
  start-page: 573
  issue: 2
  year: 2020
  ident: 2022012716231840800_B20
  article-title: Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
  publication-title: Leukemia.
  doi: 10.1038/s41375-020-0855-4
– volume: 136
  start-page: 35
  issue: suppl 1
  year: 2020
  ident: 2022012716231840800_B28
  article-title: Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized FORTE trial [abstract]
– volume: 132
  start-page: 2456
  issue: 23
  year: 2018
  ident: 2022012716231840800_B8
  article-title: Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
  publication-title: Blood.
  doi: 10.1182/blood-2018-06-858613
– volume: 128
  start-page: 384
  issue: 3
  year: 2016
  ident: 2022012716231840800_B18
  article-title: Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
  publication-title: Blood.
  doi: 10.1182/blood-2015-12-687749
– volume: 7
  start-page: 311
  issue: 2
  year: 2015
  ident: 2022012716231840800_B16
  article-title: Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
  publication-title: MAbs.
  doi: 10.1080/19420862.2015.1007813
– volume: 395
  start-page: 132
  issue: 10218
  year: 2020
  ident: 2022012716231840800_B11
  article-title: Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(19)32956-3
– ident: 2022012716231840800_B22
– volume: 123
  start-page: 3073
  issue: 20
  year: 2014
  ident: 2022012716231840800_B4
  article-title: Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
  publication-title: Blood.
  doi: 10.1182/blood-2014-01-550020
– volume: 35
  start-page: 2900
  issue: 25
  year: 2017
  ident: 2022012716231840800_B5
  article-title: Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2016.69.2517
– volume: 31
  start-page: 2540
  issue: 20
  year: 2013
  ident: 2022012716231840800_B3
  article-title: Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2012.46.2119
– volume: 378
  start-page: 518
  issue: 6
  year: 2018
  ident: 2022012716231840800_B23
  article-title: Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1714678
– volume: 20
  start-page: e30
  issue: 1
  year: 2020
  ident: 2022012716231840800_B9
  article-title: Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis
  publication-title: Clin Lymphoma Myeloma Leuk.
  doi: 10.1016/j.clml.2019.09.622
– volume: 112
  start-page: 4017
  issue: 10
  year: 2008
  ident: 2022012716231840800_B2
  article-title: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
  publication-title: Blood.
  doi: 10.1182/blood-2008-05-159624
– volume: 15
  start-page: e538
  issue: 12
  year: 2014
  ident: 2022012716231840800_B24
  article-title: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(14)70442-5
– volume: 376
  start-page: 1311
  issue: 14
  year: 2017
  ident: 2022012716231840800_B1
  article-title: Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1611750
– volume: 95
  start-page: 279
  issue: 3
  year: 2019
  ident: 2022012716231840800_B19
  article-title: High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action
  publication-title: Cytometry A.
  doi: 10.1002/cyto.a.23693
– volume: 186
  start-page: 1840
  issue: 3
  year: 2011
  ident: 2022012716231840800_B14
  article-title: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.1003032
– volume: 380
  start-page: 2104
  issue: 22
  year: 2019
  ident: 2022012716231840800_B10
  article-title: Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1817249
– volume: 124
  start-page: 3474
  issue: 21
  year: 2014
  ident: 2022012716231840800_B15
  article-title: Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
  publication-title: Blood.
  doi: 10.1182/blood.V124.21.3474.3474
– volume-title: Package insert.
  year: 2020
  ident: 2022012716231840800_B21
– volume: 197
  start-page: 807
  issue: 3
  year: 2016
  ident: 2022012716231840800_B17
  article-title: The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.1501351
– volume: 20
  start-page: 1467
  issue: 9
  year: 2006
  ident: 2022012716231840800_B25
  article-title: International uniform response criteria for multiple myeloma [corrections published in Leukemia. 2006;20:2220 and Leukemia. 2007;21:1134]
  publication-title: Leukemia.
  doi: 10.1038/sj.leu.2404284
– volume: 17
  start-page: e328
  issue: 8
  year: 2016
  ident: 2022012716231840800_B13
  article-title: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30206-6
– volume: 10
  start-page: 860
  year: 2020
  ident: 2022012716231840800_B12
  article-title: Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2020.00860
– volume-title: clonoSEQ® Assay Technical Information.
  year: 2018
  ident: 2022012716231840800_B27
– volume: 3
  start-page: 28
  issue: 1
  year: 2017
  ident: 2022012716231840800_B6
  article-title: Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2016.3160
– volume: 51
  start-page: 1565
  issue: 12
  year: 2016
  ident: 2022012716231840800_B7
  article-title: Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2016.222
– volume: 117
  start-page: 4691
  issue: 18
  year: 2011
  ident: 2022012716231840800_B26
  article-title: Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
  publication-title: Blood.
  doi: 10.1182/blood-2010-10-299487
– reference: 35084473 - Blood. 2022 Jan 27;139(4):469-471. doi: 10.1182/blood.2021013199
SSID ssj0014325
Score 2.6322477
Snippet In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA...
San Miguel et al evaluated the impact of dynamic, rather than single-point, assessment of measurable/minimal residual disease (MRD) by next-generation...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 492
SubjectTerms Aged
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Clinical Trials and Observations
Female
Humans
Male
Middle Aged
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Neoplasm, Residual - diagnosis
Neoplasm, Residual - drug therapy
Progression-Free Survival
Treatment Outcome
Title Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
URI https://dx.doi.org/10.1182/blood.2020010439
https://www.ncbi.nlm.nih.gov/pubmed/34269818
https://www.proquest.com/docview/2552995509
https://pubmed.ncbi.nlm.nih.gov/PMC8796656
Volume 139
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEJcXBB2XcpOREBJCYYudNMljqDoNaDuhtdJ4iuzE2YraBK1JpfLKH-f4kku3MQ1eIsu1XUvni_MdnxtCbzl1_KAfECtxubAcFlPL505gCeKLVBCP7atA2vGkfzhzvpy4J53OpuW1VBb8Y_zryriS_5Eq9IFcZZTsP0i2XhQ6oA3yhSdIGJ43kvGxjn4CzigzhCxVjv6Vjq4yhpcPmTitCkTMM1k_fLGR963SvU5Oq9wJlxuxyJes9qdsgicTmRu8XJZLxuUK4_BzqEaFo8H3o8lwyyi8MJXn1ZUNy6zx_LQUxolmVdbsPVyLwhrlcoel_vSdr7XBvmXQWjMDvSxvzE3GHfz4jP2Yt-8riHT8sHT4f3XEypzY-0RbY8QVfdW5rLMcGQA6rVPW0eXzLp_-vswmqzz-QfMnKveQWWQr0fbkKDqYjUbRdHgyvYVuE9AwZPGLr98aA5RDVb3eemOVhdsnexfX_xujuayxXHS8bTGZ6UP0wKggONR4eoQ6Iuui3TBjRb7c4HdYOQUra0sX3flUte4NqtKAXXR3bDwydtHvGoPYYBBXGMQGg7jBIJ5nWGEQ1xjEFQaxwSAGdGHAINYYxHmKWxiUK0gMqlEGg4_R7GA4HRxaprCHFbs2LSzKmZsGTpowzyZekjhwUHgJS4Hu-5wKaHGW9oUtbEdWC4ipm6a2LQIvpimJA58-QTtZnolnCHMGHFa48N1h3Ik5fG2ILUgQM-p4QlDaQ3uVcKLYZL2XxVcWkdJ-fRIpcUaNOHvofT3jp874cs1YWsk7MoxVM9EIIHnNrDcVNCIQnLTQsUzk5SoC_R7ooQskvoeeaqjUe6Ay6BzodQ95WyCqB8hE8du_ZPMzlTDe94I-6G3Pb_C_L9D95qV9iXaK81K8Atpd8NfqBfkDD6nb8Q
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sustained+minimal+residual+disease+negativity+in+newly+diagnosed+multiple+myeloma+and+the+impact+of+daratumumab+in+MAIA+and+ALCYONE&rft.jtitle=Blood&rft.au=San-Miguel%2C+Jesus&rft.au=Avet-Loiseau%2C+Herv%C3%A9&rft.au=Paiva%2C+Bruno&rft.au=Kumar%2C+Shaji&rft.date=2022-01-27&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=139&rft.issue=4&rft.spage=492&rft_id=info:doi/10.1182%2Fblood.2020010439&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon